Source disclosure: February 13, 2026
TMS Co.,Ltd. [4891.T]
TOKYO, Feb 13 (Pulse News Wire) – TMS CO.,LTD. (4891.T) reported its fiscal year ending December 2025 results, showing a reduction in operating expenses compared to initial forecasts.
Operating losses decreased by --¥71 million percent year-over-year, despite a ten-month reporting period due to the shift in the fiscal year-end from February to December. The company also highlighted progress in clinical trials for TMS-007 (JX10). Global Phase 2/3 trials began on May 16, 2025, with the first dose administered globally. As of December 8, 2025, 59 patients had been enrolled, surpassing expectations. TMS expects to complete Part 1 (Phase 2) enrollment by the end of 2026.
In addition, TMS announced that CORXEL, a subsidiary partially owned by RTW Investments, secured $287 million in funding on January 22, 2026. This financing will support the development of TMS-007 and other pipeline candidates, including CX11 for obesity treatments. Notably, this round included participation from renowned investors such as SR One, TCG Crossover, RA Capital Management, and others. Cash flow improved significantly due to fundraising activities, resulting in a net cash balance of ¥2.700 billion at the end of the reporting period, down slightly from the beginning of the year. Despite increased research and development expenditures, the company's overall financial position remains stable.
AI-translated content. 🔴 Confidence: Review recommended See terms • Original filing